Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Systemic Sclerosis: Early Recognition, Systemic Screening, and Multidisciplinary Management

Description

The talk emphasized that dermatologists are often the first to detect systemic sclerosis, making early recognition and systematic screening essential because major morbidity and mortality come from internal organ involvement. The speaker reviewed clinical clues such as puffy fingers, hand swelling, Raynaud’s phenomenon, nailfold changes, telangiectasias, calcinosis, distal or proximal skin thickening, and digital ulcers, and explained the distinction between limited and diffuse cutaneous disease: diffuse disease is more likely to have early interstitial lung disease and renal crisis, while limited disease more often carries long-term risk of pulmonary hypertension and vascular complications. Autoantibodies help with risk stratification, with anti-Scl-70 linked to diffuse disease and ILD, anticentromere to limited disease and pulmonary hypertension, and anti-RNA polymerase III to renal crisis and malignancy risk. The talk covered major extracutaneous manifestations affecting the skin, lungs, kidneys, GI tract, heart, and vasculature, including the need to ask targeted review-of-systems questions, monitor blood pressure and renal function, and screen routinely with pulmonary function tests, high-resolution CT when indicated, echocardiography, NT-proBNP, EKG, and sometimes cardiac MRI. Management was presented as multidisciplinary and organ-driven: calcium channel blockers, PDE5 inhibitors, and botulinum toxin for Raynaud’s and digital vasculopathy; mycophenolate as common first-line therapy especially for ILD; methotrexate for skin-predominant disease with caution in ILD; and selected use of rituximab, tocilizumab, or antifibrotic therapy. The speaker stressed avoiding higher-dose systemic steroids because of renal crisis risk and concluded that coordinated care across dermatology, rheumatology, pulmonology, cardiology, GI, and nephrology improves outcomes.

View more

Conclusions

Systemic sclerosis is a multisystem disease in which skin findings often appear first, but outcomes are largely determined by internal organ involvement.
Dermatologists are in a key position to recognize early systemic sclerosis and trigger screening before major organ damage develops.
Limited and diffuse cutaneous subtypes help predict likely complications, with diffuse disease tending toward earlier lung and renal involvement and limited disease toward later pulmonary hypertension and vascular disease.
Autoantibody profiles can help stratify risk, but every patient still requires comprehensive evaluation regardless of serology.
Systematic screening for extracutaneous disease should include targeted history, focused exam, and low-threshold referral to rheumatology and other specialists.
Digital vasculopathy and Raynaud’s are common and often require stepwise treatment, including calcium channel blockers, PDE5 inhibitors, and sometimes botulinum toxin.
Gastrointestinal involvement is frequent and may be underreported, so clinicians should actively ask about reflux, dysphagia, bloating, and bowel dysfunction.
Pulmonary disease is a major driver of morbidity and mortality, making routine surveillance for ILD and pulmonary hypertension essential.
Mycophenolate is generally the preferred first-line treatment for systemic sclerosis–associated ILD, while other agents are reserved for selected cases.
Scleroderma renal crisis is uncommon but life-threatening, occurs more often in early diffuse disease, and requires blood pressure and kidney monitoring with caution around higher-dose steroids.
Cardiac involvement can be subtle yet clinically important, supporting routine cardiac screening and multidisciplinary co-management.
Overall, early recognition and coordinated multidisciplinary care are central to improving outcomes in systemic sclerosis.

Denton CP, Khanna D. Lancet. 2017;390:1685-1699.
Roofeh D, David et al. Treatment of systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Journal of Scleroderma and Related Disorders. 2020.#10.1177/2397198320903208